Last Update Time:
28-Feb-2025 16:00:00
ISIN:
INE572A01036
Sector:
Healthcare
Symbol:
JBCHEPHARM
JB Chemicals & Pharmaceuticals Limited
₹1,653.75
₹75.95
(4.81%)
▲
Prev. Close
₹1,577.80
Open
₹1,577.50
Close
₹1,644.35
Range
₹1,571.06 - ₹1,736.44
High
₹1,667.20
Low
₹1,525.25
Ind. Close
₹0.00
VWAP
₹1,608.32
The current stock price of JB Chemicals & Pharmaceuticals Limited is ₹1,653.75, with a target price range between ₹1,571.06 and ₹1,736.44. The stock has experienced a price change of ₹75.95 (4.81%), reflecting recent market volatility.
Today's opening price was ₹1,577.50, while the previous close stood at ₹1,577.80.
The market trend suggests an uptrend, making it an attractive investment opportunity for traders seeking short-term gains.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
JB Chemicals & Pharmaceuticals Limited Price Chart
JB Chemicals & Pharmaceuticals Limited Pre Open Market Overview: 28-Feb-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1577.5
- Previous Close Price: 1577.8
- Change: -0.30%
- Total Traded Volume: 265
- Total Buy Quantity: 850
- Total Sell Quantity: 2,597
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,554.95 | 2.00 | 0.00 |
| 1,560.00 | 20.00 | 0.00 |
| 1,560.80 | 2.00 | 0.00 |
| 1,563.50 | 25.00 | 0.00 |
| 1,575.00 | 2.00 | 0.00 |
| 1,577.50 | 0.00 | 126.00 |
| 1,577.55 | 0.00 | 26.00 |
| 1,577.80 | 0.00 | 230.00 |
| 1,578.80 | 0.00 | 1.00 |
| 1,579.90 | 0.00 | 1.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 850
Total Sell Quantity: 2597
Shareholding Patterns of JB Chemicals & Pharmaceuticals Limited
Key Trade Statistics of JB Chemicals & Pharmaceuticals Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 2.17 |
| Traded Value (₹ Cr.) | 34.89 |
| Total Market Cap (₹ Cr.) | 25,733.40 |
| Free Float Market Cap (₹ Cr.) | 11,804.45 |
| Impact cost | 0.06 |
| Quantity Traded | 216,953.00 |
| Deliverable Quantity | 112,865.00 |
| % of Quantity to Traded | 52.02 |
| Security VaR | 11.62 |
| Index VaR | N/A |
| VaR Margin | 11.62 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 15.12 |
| Face Value | 1 |
Key Price Statistics of JB Chemicals & Pharmaceuticals Limited
The 52-week high for JB Chemicals & Pharmaceuticals Limited was ₹2,030.00, recorded on 16-Aug-2024. On the other hand, the 52-week low stands at ₹1,480.00, with the lowest value recorded on 29-Feb-2024.
The upper band for trading is ₹1,893.35, and the lower band is ₹1,262.25. The price band is 20%.
The stock's daily volatility stands at 1.83, while the annualized volatility is 34.96. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (16-Aug-2024) | 2,030.00 |
| 52 Week Low (29-Feb-2024) | 1,480.00 |
| Upper Band | 1,893.35 |
| Lower Band | 1,262.25 |
| Price Band (%) | 20 |
| Daily Volatility | 1.83 |
| Annualised Volatility | 34.96 |
| Tick Size | 0.05 |
Key Securities Statistics of JB Chemicals & Pharmaceuticals Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 29-Apr-2003 |
| Adjusted P/E | 38.36 |
| Symbol P/E | 38.36 |
| Index | NIFTY PHARMA |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of JB Chemicals & Pharmaceuticals Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of JB Chemicals & Pharmaceuticals Limited
| Subject | Date |
|---|---|
| General Updates | 28-Feb-2025 |
| Alteration Of Capital and Fund Raising-XBRL | 27-Feb-2025 |
| ESOP/ESOS/ESPS | 27-Feb-2025 |
| General Updates | 19-Feb-2025 |
| General Updates | 19-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 10-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 05-Feb-2025 |
| Copy of Newspaper Publication | 05-Feb-2025 |
Corporate Actions of JB Chemicals & Pharmaceuticals Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Interim Dividend - Rs 8.50 Per Share | 07-Feb-2025 |
| 1 | Dividend - Rs 6.75 Per Share | 14-Aug-2024 |
| 1 | Interim Dividend - Rs 5.50 Per Share | 16-Feb-2024 |
| 1 | Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share | 18-Sep-2023 |
| 1 | Dividend - Rs 9.25 Per Share | 17-Aug-2023 |
| 1 | Interim Dividend - Rs 8.50 Per Share | 17-Feb-2023 |
| 1 | Dividend - Rs 8 Per Sh | 12-Aug-2022 |
| 1 | Interim Dividend - Rs 8.50 Per Share | 23-Feb-2022 |
| 1 | Annual General Meeting/Dividend - Rs 8 Per Share | 01-Sep-2021 |
| 1 | Interim Dividend - Rs. 8.50 Per Share | 18-Feb-2021 |
| 1 | Annual General Meeting/Dividend - Re 1 Per Share | 22-Sep-2020 |
| 1 | Interim Dividend - Rs 10 Per Share | 03-Mar-2020 |
| 1 | Buyback | 21-Nov-2019 |
| 1 | Dividend - Rs 5 Per Share | 14-Aug-2019 |
| 1 | Buyback | 11-Sep-2018 |
| 1 | Dividend Rs 2/- Per Share | 27-Aug-2018 |
| 1 | Annual General Meeting/Dividend - Re 1/- Per Share | 11-Sep-2017 |
| 1 | Buyback | 01-Jun-2017 |
| 1 | Dividend - Re 0.50/- Per Share | 11-Aug-2016 |
| 1 | Interim Dividend -Rs 4.50/- Per Share (Purpose Revised) | 17-Mar-2016 |
Board Meetings of JB Chemicals & Pharmaceuticals Limited
Financial Results of JB Chemicals & Pharmaceuticals Limited
Company Directory of JB Chemicals & Pharmaceuticals Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.jbpharma.com | Head Office/ Corporate Office | Cnergy IT Park, Unit A2, 3rd Floor, Appa Saheb Marathe Marg, Prabhadevi Mumbai 400 025 | MUMBAI |
| www.jbpharma.com | Registered Office | Neelam Centre, 4th Floor, B Wing Hind Cycle Road Worli | MUMBAI |
| www.jbpharma.com | Transfer Agent | Datamatics Business Solutions Ltd. Plot No. B-5, Part B Cross Lane, MIDC, Andheri(E), | MUMBAI |
Insider Trading of JB Chemicals & Pharmaceuticals Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Sandeep Phadnis | 1683700 | Pledge Revoke |
| 7(2) | Nikhil Chopra | 86380000 | Pledge |
| 7(2) | Jason Nestor Vincent D'Souza | 12438720 | Pledge |
| 7(2) | Jason Nestor Vincent D'Souza | 13010040 | Buy |
| 7(2) | Nikhil Chopra | 90347500 | Buy |
| 7(2) | Himanshu Praful Ranvah | 724000 | Sell |
| 7(2) | Sandeep Nasa | 75780470 | Sell |
| 7(2) | Suresh Amin | 448025 | Sell |
| 7(2) | Suresh Amin | 93000 | Sell |
| 7(2) | Manish Dinesh Shah | 1545183 | Sell |
| 7(2) | Nikhil Chopra | 9182000 | Sell |
| 7(2) | Nikhil Chopra | 9182000 | Pledge Revoke |
| 7(2) | Sandeep Phadnis | 3838562 | Sell |
| 7(2) | Sandeep Phadnis | 3838562 | Pledge Revoke |
| 7(2) | Bharat Dhanani | 7302000 | Sell |
| 7(2) | Bharat Dhanani | 7302000 | Pledge Revoke |
| 7(2) | Parasram Balaji Borge | 425967 | Sell |
| 7(2) | Parasram Balaji Borge | 425967 | Pledge Revoke |
| 7(2) | Nikhil Chopra | 18455420 | Pledge Revoke |
| 7(2) | Bharat Dhanani | 3715000 | Pledge Revoke |
Annual Reports of JB Chemicals & Pharmaceuticals Limited
Investor Complaints of JB Chemicals & Pharmaceuticals Limited
Event Calendar of JB Chemicals & Pharmaceuticals Limited
| Purpose | Details |
|---|---|
| Results/Dividend | The Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on May 23, 2011 to consider and approve annual audited financial results for the year ended on March 31, 2011. The Company has now informed the Exchange that the Board of Directors of the Company at the aforesaid meeting to be held on May 23, 2011 would also consider recommendation of dividend for the year 2010-11. (Purpose Revised). |
| Dividend | To consider, amongst other things, declaration of Special Interim Dividend. |
| Results/Dividend | The Company had informed the Exchange regarding a Board meeting to be held on May 23, 2012 to consider and approve annual audited financial results for the year ended on March 31, 2012. The Company has now informed the Exchange that at the aforesaid board meeting the Board would also consider recommendation of final dividend for the year 2011-12 (Purpose Revised). |
| Results/Dividend | Inter alia, to consider and approve annual audited financial results for the year ended on March 31, 2013 and also to consider recommendation of dividend for the year 2012-13. |
| Results | To consider and approve annual audited financial results for the year ended on March 31, 2013. |
| Results | To approve and take on record the unaudited financial results for the quarter ended on June 30, 2013. |
| Results | To approve and take on record the unaudited financial results for the quarter / half year ended on September 30, 2013. |
| Results | To approve and take on record the unaudited financial results for the quarter/ nine months ended on December 31, 2013. |
| Results/Dividend | Inter alia, to consider and approve annual audited financial results for the year ended on March 31, 2014 and also to consider recommendation of dividend for the year 2013-14. |
| Results | To consider and approve unaudited financial results for the quarter ending on June 30, 2014. |
| Results | to consider and approve unaudited financial results for the quarter ended on September 30, 2014. |
| Results | To consider and approve unaudited financial results for the quarter ending on December 31, 2014. |
| Results/Dividend | To consider and approve annual audited financial results for the year ended on March 31, 2015. This is to further intimate the Exchange that the board of directors will also consider recommendation of dividend at the said meeting. |
| Results | To consider and approve unaudited financial results for the quarter ended on June 30, 2015. |
| Results | To consider and approve unaudited financial results for the quarter ended on September 30, 2015. |
| Results | To consider and approve unaudited financial results for the quarter ended on December 31, 2015. |
| Dividend | Inter alia, consider and declare interim dividend for the financial year 2015-16. |
| Results | inter alia, to consider and approve audited financial statements for the year ended on March 31, 2016. |
| Results/Dividend | The Company had informed the Exchange regarding a meeting of the Board of Directors of the Company schedule to be held May 20 , 2016 inter alia, to consider and approve audited financial statements for the year ended on March 31, 2016. The Company has now informed the Exchange that the meeting of the Board of Directors would also consider recommendation of final dividend for the F.Y. 2015-16(purpose revised) |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on June 30, 2016. |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on September 30, 2016. |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on December 31, 2016. |
| Results/Dividend | inter alia, to consider and approve audited financial statement for the year ended on March 31, 2017 and also consider recommendation of dividend for the F.Y. 2016-17. |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on June 30, 2017. |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on September 30, 2017. |
| Results | To, inter alia, consider and approve unaudited financial results for the quarter ended on December 31, 2017. |
| Dividend | To consider dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2019 |
| Dividend | This is to intimate you that the Board of Directors of the Company at its meeting to be held on May 21, 2019, would also consider recommendation of dividend for the F.Y. 2018-19. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Buyback | To consider buyback for equity shares |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | To consider and declare interim dividend |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Dividend | Recommendation of final dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Dividend | Board to consider declaration of Interim Dividend |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Other business matters | Board meeting intimation for consideration of Employee Stock Option Scheme |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2021 |
| Dividend | Recommendation of final dividend |
| Financial Results | To consider and approve unaudited financial results for the quarter ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Dividend | To consider and approve (i) unaudited financial results for the period ended December 31, 2021 and (ii) declaration of interim dividend, if any |
| Financial results | J. B. Chemicals & Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 04-Aug-2022 to consider and approve unaudited financial results for the quarter ended on June 30, 2022 |
| Financial results | J. B. Chemicals & Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider and approve unaudited financial results for the quarter and half year ended September 30, 2022 |
| Financial Results/Dividend | To consider and approve the (i) Unaudited financial results for the quarter ended on December 31, 2022; and (ii) Declaration of Interim dividend, if any, for the financial year 2022-23 |
| Financial Results/Dividend | To consider and approve audited financial results for the year and quarter ended on March 31, 2023, recommendation of final Dividend on equity shares of the Company, if any, and consideration and approval of the proposal to sub-divide/split the equity shares |
| Stock Split | To consider and approve audited financial results for the year and quarter ended on March 31, 2023, recommendation of final Dividend on equity shares of the Company, if any, and consideration and approval of the proposal to sub-divide/split the equity shares |
| Financial Results | To consider and approve the unaudited financial results for the quarter ended June 30, 2023 |
| Financial Results | To consider and approve the unaudited financial results for the quarter and half year ended on September 30, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and dividend |
| Financial Results/Dividend | To consider and approve the audited financial results for the year and quarter ended March 31, 2024 and consideration and recommendation of dividend on equity shares of the Company, if any, subject to approval of shareholders |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results/Dividend | To consider and approve the unaudited financial results for the period ended December 31, 2024 and to consider interim dividend, if any, for the financial year 2024-25 |
Share Transfers of JB Chemicals & Pharmaceuticals Limited
Voting Results of JB Chemicals & Pharmaceuticals Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 21-AUG-2024 | AGM | (a)Adoption of standalone audited financial statements for the year ended on March 31, 2024, and reports of Board of Directors and auditors￢ﾀﾙ thereon.n(b) Adoption of consolidated audited financial statements for the year ended on March 31, 2024, and report of auditors￢ﾀﾙ thereon. |
| 21-AUG-2024 | AGM | Ratification of remuneration of cost auditor. |
| 21-AUG-2024 | AGM | Approval of revision in remuneration of Mr. Nikhil Chopra (DIN: 07220097) Chief Executive Officer and Whole-Time Director of the Company, for the financial year 2024-25. |
| 21-AUG-2024 | AGM | Re-appointment of Mr. Prashant Kumar (DIN: 08342577) as a Director of the Company liable to retire by rotation. |
| 21-AUG-2024 | AGM | Declaration of final dividend of Rs. 6.75/- per equity share of face value Re. 1/- each, for the year ended on March 31, 2024. |
| 21-AUG-2024 | AGM | Confirmation of interim dividend of Rs. 5.50/- per equity share of face value Re. 1/- each, for the year ended on March 31, 2024. |
| 05-JUL-2024 | Postal Ballot | Appointment of Mr. Arun Duggal (DIN: 00024262) as a Non-Executive Independent Director of the Company |
| 07-APR-2024 | Postal Ballot | To approve appointment of Mr. Akshay Tanna (DIN: 02967021) as Non-Executive, Non-Independent Director of the Company. |
| 20-DEC-2023 | Postal Ballot | To approve amendment to the Company's Employee Stock Option Scheme titled JBCPL Employee Stock Option Scheme 2021 ( Scheme or ESOP 2021 ) |
| 24-AUG-2023 | AGM | (a)Adoption of standalone audited financial statements for the year ended on March 31, 2023, and reports of Board of Directors and auditors￢ﾀﾙ thereon.n(b) Adoption of consolidated audited financial statements for the year ended on March 31, 2023, and report of auditors￢ﾀﾙ thereon. |
| 24-AUG-2023 | AGM | Ratification of remuneration of cost auditor. |
| 24-AUG-2023 | AGM | Approval of revision in remuneration of Mr. Nikhil Chopra (DIN: 07220097) Chief Executive Officer and Whole-Time Director of the Company, for the financial year 2023-24. |
| 24-AUG-2023 | AGM | Sub-division of equity shares from face value of Rs. 2/- each to Re 1/- each and consequential amendment in Memorandum of Association of the Company. |
| 24-AUG-2023 | AGM | Re-appointment of Mr. Gaurav Trehan (DIN: 03467781) as a Director of the Company liable to retire by rotation. |
| 24-AUG-2023 | AGM | Declaration of final dividend of Rs. 9.25/- per equity share of face value Rs. 2/- each, for the year ended on March 31, 2023. |
| 24-AUG-2023 | AGM | Confirmation of interim dividend of Rs. 8.50/- per equity share of face value Rs. 2/- each, for the year ended on March 31, 2023. |
| 24-AUG-2022 | AGM | (a)Adoption of standalone audited financial statement for the year ended on March 31, 2022, and reports of Board of Directors and auditors￢ﾀﾙ thereon.n(b) Adoption of consolidated audited financial statement for the year ended on March 31, 2022, and report of auditors￢ﾀﾙ thereon. |
| 24-AUG-2022 | AGM | Re-appointment of Mr. Prashant Kumar (DIN: 08342577) as a director of the Company liable to retire by rotation. |
| 24-AUG-2022 | AGM | Declaration of final dividend of Rs. 8.00/- per equity share of face value Rs. 2/- each, for the year ended on March 31, 2022. |
| 24-AUG-2022 | AGM | Confirmation of interim dividend of Rs. 8.50/- per equity share of face value Rs. 2/- each, for the year ended on March 31, 2022. |
FAQs on JB Chemicals & Pharmaceuticals Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.